Bristol Myers Squibb discontinues its Prothena-partnered neurological drug program as stronger-than-expected third-quarter results help lift the company’s sales outlook and improve its near-term commercial prospects

Bristol Myers Squibb discontinues its Prothena-partnered neurological drug program as stronger-than-expected third-quarter results help lift the company’s sales outlook and improve its near-term commercial prospects